Weight Management and Tirzepatide (Mounjaro)

Posted on:

As of 23rd June 2025, a new weight loss drug called Tirzepatide (also known as Mounjaro) is available for use in primary care settings. Tirzepatide is being rolled out nationally over a few years. Initially it will only be available on the NHS to a very small number of patients with the highest medical need. This is to allow safe entry of this repurposed medicine into the health system.

Please only contact us if you are eligible, this means you have a BMI of 40 or higher and at least four of these additional conditions, which will already have been diagnosed by your GP or another medical professional:

  • Atherosclerotic cardiovascular disease (ASCVD)
  • Hypertension
  • Dyslipidaemia
  • Obstructive Sleep Apnoea (OSA)
  • Type 2 diabetes